Faron Pharmaceuticals Oy Share Discussion Threads

[genierub] 28/11/2019 14:01

Its about to move again. Good luck all. Money is finally loading up.

[davidlloyd] 28/11/2019 09:31

Hash - :-)

DL

[latifs100] 28/11/2019 09:28

whats target price now?

[hashertu] 28/11/2019 09:18

DL. I think there is disappointment that the IND did not include the use of Clevegen to treat investors who suffer from refractory apathy.

[davidlloyd] 28/11/2019 08:11

Quiet here still?
DL

[hashertu] 26/11/2019 16:11

There are plenty of drug manufacturers in the world.
I do not think finding a new supplier will be a significant problem if the trial design is approved and funding for same is found.

[learner9] 26/11/2019 12:09

Hi. They are the current API Manufacturer (Rentschler Biopharma) who have terminated the supply agreement due to "the significant upgrading of the API process that is required". So if Faron are currently single sourced, that sounds like a lot of work/potential delays.

[daffodil4] 26/11/2019 08:29

The undisclosed investors in the latest placing presumably
all took under 3%...so now they can sell on the
Helsinki Nasdaq without having to declare shortly...
Will those trades show on this site???? Thanks!

[hashertu] 25/11/2019 16:26

Learner9. Who is "they" in your post and what is (are) the manufacturing problem(s)?
It is pointless progressing funding, and finding a new manufacturer for Traumakine, until there is agreement with the relevant authorities for a trial that excludes corticosteroids.
That, of course, just(!) leaves Clevegen ( a potential blockbuster, or not).

[daffodil4] 25/11/2019 09:35

I agree....IMO Faron know it..otherwise why not
fund phase 3....they are only prepared to back Clevegen.
so if they do not want to put money behind it
why would anyone else. I actually do not think they
are expecting the go ahead for another trial..
something does not add up...it is all about Clevgen
now.

[learner9] 23/11/2019 22:35

My view is Traumakine is dead. They do not understand the manufacture problems , so no one is going to eat to fund it

[mister md] 20/11/2019 12:58

last Friday these were still at placing price of 190p, I expect thats the first target

[this1] 20/11/2019 12:39

Ownership per institution was left under 3 % which is the minimum amount you have to own to have to make a TR1. This means there were several institutions that took part to the placement since Faron gave out 10 % of the sharecapital.I think the institutions are now hungry for more shares since they didn't get enough and these shares they have to buy from market because Faron agreed with Carnegie not to make any additional offerings for the next 6 months (no dillution at least for the next 6 months). Smart

[daffodil4] 20/11/2019 11:46

Any thoughts why there were no details
of who bought the placement shares
besides the few mentioned in the
placing result RNS??

[mister md] 20/11/2019 11:12

NY Boy - good luck with your 125p. Last time it bounced from 150p to 277p. Seems 150p was the bottom so perhaps good entry point here

[ih_615088] 20/11/2019 08:02

DNL = RALLLLLLLLLLLLLLLLLLLLLLLLLLLLL and more news are imminent see below ...


Diurnal (DNL) Price:30p --Market Cap £26 M --Cash £9 M--MEGA milestones expected within 4 weeks = 300-500% GEM

Approaching anumber of near-term milestones....5 November 2019



DITEST™(Hypogonadism) study readout Q4 2019

Alkindi® US NDA submission to the FDA(paediatric AI,including CAH)Q4 2019

Chronocort® European regulatory submission to the EMA(CAH)Q4 2019

Conclude US partnering discussions for Alkindi®(Chronocort®)H1 2020


Presentation
hxxps://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf

[ny boy] 19/11/2019 17:17

Next support is 125p, wouldn’t buy until then.

[daffodil4] 19/11/2019 09:36

I think Farn is all about Clevegen now...
They have no funds or plans to fund Traumakine
IF they get the go ahead for another phase 3 trial..
Other than saying a Third Party would fund
future development...
Clevegen is in very early stage, so years away
from being commercial. They have been talking for a
long time now about potential Partners, but still
no deal has been agreed.. They did well to place
at £1.90 but unless they get the go ahead and
a Partner to fund Traumakine then this will
struggle to keep the current share price and would
imagine 80p-£1 would be seen by the year end!

[latifs100] 18/11/2019 13:57

so valatile.only for the brave

[cwebb07] 18/11/2019 13:43

Big tree shake todayToo much info to come and someone buying up alot of stockPotential double share price from here in a short space of time

[monster500] 18/11/2019 12:24

I agree. Company stated can't justify the initial rise. I'm afraid it may go back to 85p. Not looking good :(

[toffeeman] 18/11/2019 11:48

If 160 goes then it's 130 and if that fails to support then 100. Very relieved I sold when I did

[milliecusto] 15/11/2019 13:38

It's to big a drop, maybe delay of partner news or bad news on the drug front, this share could quickly drop to £1 then rise up

[latifs100] 15/11/2019 13:24

what caused the drop today

[milliecusto] 15/11/2019 10:47

A lot of short am selling going on